Thousand Oaks, California-based Latigo Biotherapeutics has filed for a Nasdaq IPO seeking to raise approximately $272 million through the sale of 16.0 million shares priced between $16.00 and $18.00 each. At the midpoint of the proposed range, the company would have an implied market capitalization of approximately $1.02 billion. Latigo intends to trade on the Nasdaq Global Select Market under the ticker LTGO, with the offering being led by Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities.
Pain management remains one of the largest therapeutic markets in healthcare, with an estimated 250 million pain prescriptions written annually in the United States. Despite decades of innovation across medicine, opioids continue to serve as the standard of care for many acute pain indications, contributing to an ongoing public health crisis driven by addiction, overdose, and dependence. Latigo Biotherapeutics is developing a new generation of non-opioid pain medicines designed to interrupt pain signaling without the addictive properties associated with traditional opioid therapies. Its platform is built around selective Nav1.8 inhibitors, a validated target that has emerged as one of the most promising new approaches in pain management following the FDA approval of the first drug in the class in 2025.
The company's lead product candidate, LTG-001, is being developed for the treatment of moderate-to-severe acute pain, including postoperative pain. Designed as an oral, fast-acting Nav1.8 inhibitor, LTG-001 aims to provide effective pain relief while reducing or eliminating the need for opioids. Recently reported results from a randomized Phase 2 clinical trial in 343 abdominoplasty patients demonstrated that the high-dose regimen met its primary endpoint while producing approximately 50% greater analgesic effect than Vicodin, faster onset of meaningful pain relief, and an opioid-free rate exceeding 52% during the 48-hour treatment period. These results position LTG-001 among the more closely watched non-opioid pain candidates currently in clinical development.
Building on these encouraging data, Latigo plans to initiate both a Phase 3 bunionectomy efficacy trial and a Phase 3 open-label safety study during the second half of 2026, with topline results expected during the second half of 2027. If successful, these studies would support a future New Drug Application (NDA) seeking FDA approval for LTG-001 in moderate-to-severe acute pain. The company is also developing an intravenous formulation of LTG-001 intended to allow physicians to transition patients seamlessly from inpatient postoperative care to outpatient pain management using the same underlying therapy.
Latigo's second clinical program, LTG-321, expands the company's opportunity into the substantially larger chronic pain market. LTG-321 is a structurally distinct, once-daily Nav1.8 inhibitor currently being evaluated in a Phase 2 proof-of-concept trial for osteoarthritis of the knee, with topline results expected during the second half of 2027. The company believes LTG-321's pharmacologic profile may allow lower dosing and improved convenience compared with earlier-generation therapies, potentially making it well suited for long-term management of chronic musculoskeletal pain.
Beyond its two lead clinical programs, Latigo continues to expand its broader pain platform through LTG-418, a next-generation Nav1.8 inhibitor that may support lower doses and multiple delivery formats, including topical gels, patches, inhaled therapies, injectables, and eye drops. The company is also researching additional ion channel targets involved in peripheral pain transmission as it works toward building one of the broadest non-opioid pain pipelines in development.
Latigo has assembled an experienced leadership team with deep expertise in pain drug development, clinical trial execution, and commercialization. Chief Executive Officer Nima Farzan previously served as CEO of Kinnate Biopharma and PaxVax, while Chief Medical Officer Dr. Neil Singla has participated in more than 250 pain studies, including over 50 chronic pain trials, and has been involved in more than 75 FDA meetings related to pain therapeutics. The company is further supported by an experienced investor base that includes Westlake BioPartners, Foresite Capital, 5AM Ventures, and Blue Owl Healthcare Opportunities, which together have helped Latigo raise more than $321 million since inception.
Financially, Latigo remains a pre-revenue biotechnology company focused on advancing its clinical pipeline. Operating expenses increased from $63.5 million in 2024 to $110.4 million in 2025, resulting in net losses of $61.2 million and $109.2 million, respectively. As of March 31, 2026, the company reported $42.2 million in cash and cash equivalents, while also disclosing a preliminary unaudited cash balance of approximately $54.8 million as of June 30, 2026. Assuming pricing at the midpoint of the proposed range, Latigo expects to generate approximately $247 million in net proceeds, which management intends to use primarily to fund Phase 3 development of LTG-001, continue advancing LTG-321, expand earlier-stage pipeline programs, and support general corporate operations.
Latigo enters the public markets with one of the more differentiated biotechnology stories among recent IPO candidates. Rather than pursuing another oncology or rare disease platform, the company is focused on one of healthcare's largest unmet needs—providing effective pain relief without exposing patients to the risks of opioid addiction. While significant clinical, regulatory, and commercialization risks remain, Latigo has already generated encouraging efficacy data, established a clear late-stage development pathway, and built a diversified pipeline around a clinically validated mechanism of action. With multiple Phase 3 catalysts expected over the next two years and a management team experienced in pain drug development, Latigo will be a company investors are likely to follow closely as the next generation of non-opioid pain medicines continues to emerge.
